Tagged animal-health-solutions
Press Release
Parnell Pharmaceuticals Holdings Ltd Announces New CDMO Agreement and Business Update
Parnell announces a new contract manufacturing agreement for one animal health product and a memorandum of understanding for two additional products with a global multi-national; revenue in the first half of 2019 down 12% compared to 2018 due to timing of technology transfer revenues versus prior year; and holds 2019 guidance for a 17 - 25% increase over 2018 revenue and an EBITDA range of $7.5 - $8.5m. Read More
Press Release
Parnell Pharmaceuticals Holdings Ltd Announces Business Results for the Quarter Ended 31 March 2019
Parnell delivers 9% revenue growth in Quarter 1 of 2019 compared to 2018, and confirms provisional 2019 guidance for a 17 - 25% increase over 2018 revenue to $31 - $33 million and an EBITDA range of $7.5 - $8.5 million subject to winning at least one new Contract Manufacturing agreement in 2019. Read More
Press Release
Parnell Pharmaceuticals Holdings Ltd Announces Business Results for the Year Ended 31 December 2018 and 2019 Guidance.
Parnell delivers 39% revenue growth and a $6.5 million improvement in EBITDA in 2018 compared to 2017, returns to NPAT profitability, and provides provisional 2019 guidance for a 17 - 25% increase over 2018 revenue to $31 - $33 million and an EBITDA range of $7.5 - $8.5 million. Read More
Press Release
Parnell Pharmaceuticals Holdings Ltd Announces Business Results for the Three Months Ended 30 September 2018
Parnell delivers 39% revenue growth and a $5.9 million year-to-date improvement in EBITDA as at the third quarter of 2018 compared to the same period in 2017, consolidates the return to profitability, and maintains full-year 2018 guidance at a 35 - 40% increase over 2017 revenue to $26 - $27 million and an EBITDA range of $5.5 - $6.5 million. Read More
Press Release